Global MicrosclerotherapyTreatment Market Restraints
Factors such as side effects andhigh treatment costs are expected to restrain the global MicrosclerotherapyTreatment Market growth. According to the Journal of Phelbolymphology(2017), around 1-10% patients reported matting and residual pigmentation ascomplications post microsclerotherapy treatment. The treatments are expensive,ranging from, US$ 600 to US$ 1,200, and the cost is dependent upon the size of thevein and at least 2 to 6 treatment sessions are required with the interval of 4to 6 weeks. The procedure is a little painful while compression bandage is tobe worn post operation for several weeks which can be uncomfortable to thepatients.
Microsclerotherapy is the methodused for the treatment of telangiectasia, which is a condition where brokenblood vessels near the surface or mucous membrane appears as pink or red lineson the skin surface. Genetic and environmental factors contribute totelangiectasia. Other factors that could cause telangiectasia are aging,pregnancy, rosacea, overexposure to sunlight, and varicose veins. There is nocure for this disorder, however, can be controlled by microsclerotherapy.
Microsclerotherapy involvesinjecting a solution called 'sclerosant' using microneedles. The processinvolves the injection of sclerosant in the affected veins, which destroys theendothelium, it triggers thrombosis followed by fibrosis and this results inthe closing of the vessel. Sclerosant such as hypertonic saline solution,polidocanol, tetradecyl sulphate, and chromated glycerin are used inmicrosclerotherapy.
Some of the key manufacturersoperating in the global microsclerotherapy treatment market are Surgimedix,Inc. (microneedles), Merz Pharma GmbH & Co. KGaA (Polidocanol), QOL Medical LLC (Ethanolamineoleate), Mckesson Corporation (Sotradecol), Kreussler, Inc. (Compressionbandage), Provensis, ltd (Varithena), STD Pharmaceuticals Product Ltd.(Fibrovein injections), Medtronic plc (microneedle), Teleflex incorporatedVascular Solutions (Smartneedle vascular access system), and Boston ScientificCorporation (Interject).
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/3372
Microsclerotherapy TreatmentMarket Drivers-
Leading manufacturers areindulged in the development and commercialization of new sclerosants whichwould be used in the treatment of varicose veins such as hypertonic saline,sodium tetradecyl sulphate, and polidocanol. For instance, Medtronic Plclaunched a new product, Venaceal closure system in U.S., in November 2015. Thenew product is non-invasive and uses a proprietary medical adhesive instead ofa sclerosant to seal the varicose veins and is effective for patients sufferingfrom varicose veins by eliminating the need for anesthesia, several injections,and use of compression stockings post operation, thus reducing the disadvantagescaused by using sclerosants.
Moreover, in 2014, BTGinternational Inc. launched varithena (polidocanol) which decreases thesymptoms, appearance of varicose veins as well as achiness, itching, andswelling of the veins. Furthermore, manufacturers are also focused on inorganicgrowth strategies such as mergers and acquisitions. For instance, in August2019, Boston Scientific acquired BTG International, Inc as BTG manufactures andcommercialize products used in minimally invasive treatments used for targetingcancer and other vascular diseases.
According the National Center forBiotechnology Information (NCBI), 2019, 41% people in the U.S. suffer fromvaricose veins and around 41% of women population and 50% of the men populationall over the world, over the age of 50 have telangiectasia. According to NCBI,2018, lower limb varicose veins are very common and over 10 – 30% of the worldwide population suffers from telangiectasia. During the onset of periods andpregnancy, most of the women are prone to telangiectasia. Other reasons arestanding and sitting for long periods of time, sitting cross legged, obesity,and others. High incidence of telangiectasia is expected to boost the globalmicrosclerotherapy treatment market growth in the near future.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/microsclerotherapy-treatment-market-3372
Global MicrosclerotherapyTreatment Market Regional Analysis-
Highest incidences oftelangiectasia has been recorded in the Western Countries like Europe, Americaand Australia and this disorder is most commonly observed in females ascompared to males. According to the International Journal of PharmaceuticalSciences and Research, (2018), High prevalence of varicose veins has beenrecorded in U.S, Europe and some parts of Australia. According to the samesource, one third of the population worldwide is suffering from varicose veins,out of which, around 73% females (especially during pregnancy) and 56% malesare suffering from varicose veins.
Most of the manufacturer’sheadquarters are located in U.S. and Europe like QOL Medical LLC, MckessonCorporation, Kreussler, Inc, and Teleflex Incorporated and Boston ScientificCorporation. Therefore, introduction of existing as well as new treatmentoptions across North America and Europe is expected to drive the globalmicrosclerotherapy treatment market growth over the forecast period.
Global Microsclerotherapy TreatmentMarket Key Players-
Key players operating in theglobal microsclerotherapy treatment market are Surgimedix, Inc., Merz PharmaGmbH & Co. KGaA, QOL Medical LLC, McKesson Corporation, Kreussler, Inc.,Provensis, ltd, STD Pharmaceuticals Product Ltd., Medtronic plc, Teleflex Incorporated,and Boston Scientific Corporation.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/3372
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S. Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
